A white paper from the pharmaceutical sector explores how medical affairs teams can adjust to artificial intelligence while preserving meaningful connections with healthcare providers and patients.
The study, MedAffairs Transformation: creating a high-value medical affairs organization in the age of AI, identifies the tension between limited resources and AI’s expanding role. Although AI can improve efficiency, excessive dependence may weaken human involvement in key choices. The authors argue that teams must find a middle ground to avoid losing the human elements essential to medical engagement.
The push toward customized interactions presents both opportunity and difficulty. Pharmaceutical firms now possess tools to adapt communications for individual healthcare professionals and patients, yet expanding these initiatives without increasing complexity proves challenging. The paper insists that effective AI use requires preserving the detailed relationships that form the foundation of medical affairs work.
Operational hurdles often emerge when companies expect AI to function seamlessly at scale. Many discover that data quality and system integration pose greater obstacles than anticipated. Industry discussions frequently reference the phrase “We’ve been told we can’t touch AI,” illustrating the clash between adopting new technology and ensuring operational readiness.
For patients, AI could accelerate access to relevant information—but only if systems prioritize transparency over automation. The report cautions that poorly designed AI engagement may create gaps, leaving certain patient groups excluded.
Leadership must also address workforce preparedness. The paper stresses that ongoing training in AI skills is critical, as Elaine Ferguson, Global President of Inizio Medical, recently emphasized in an interview. Without equipping employees to adapt, firms risk falling behind competitors in an changing market.
Separate industry analyses have examined how shifting market conditions are pushing pharmaceutical companies to revise launch strategies. Another report investigates the growth of private healthcare and its effects on unmet medical needs. Meanwhile, the UK’s Most Favored Nation (MFN) policy continues to influence pricing and reimbursement frameworks for drug manufacturers.
